Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06687070 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment target: 50 to 90 Primary completion date: May 2026 to May 2027 · Completion date: May 2027 to May 2028v3 Show 2 more changesShow less
    • Primary completion date: May 2026 to May 2027
    • Completion date: May 2027 to May 2028
  2. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Nov 2024 to Dec 17, 2024 · Site details revisedv2 Show 2 more changesShow less
    • Start date changed from estimate of Nov 2024 to Dec 17, 2024
    • Site details revised
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
An open, multicenter, dose-exploring Phase I trial include Part A and Part B to evaluate the safety, tolerability and efficacy of APG-2449.
Trial Details
NCT Number NCT06687070
Lead Sponsor Ascentage Pharma Group Inc.
Conditions Platinum-resistant Recurrent Ovarian Cancer, Advanced Solid Tumor
Enrollment 90 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov